Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01143506
Other study ID # 100131
Secondary ID 10-N-0131
Status Withdrawn
Phase N/A
First received June 11, 2010
Last updated June 30, 2017
Start date June 1, 2010
Est. completion date January 4, 2012

Study information

Verified date January 4, 2012
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- The experience of volition that accompanies voluntary movement can be divided into the sense of will, or deciding to move, and the sense of agency, or feeling that the movement just made was self-generated. Very little is known regarding the neurological origin of this sense of volition. Previous research has shown that a particular part of the brain, the parietal lobe, is involved in our inner sense that we control the movements we make. Researchers are interested in determining if this sense relies on sensory information from moving fingers reaching the parietal lobe.

Objectives:

- To determine the brain regions responsible for the sense of volition and the associated sense of agency.

Eligibility:

- Healthy right-handed individuals between 18 and 55 years of age.

Design:

- The study will involve a screening visit and two testing visits. The screening visit will last 30 minutes to 1 hour, and the testing visits will each last 3 to 4 hours.

- Participants will be screened with a physical examination and medical history.

- At each testing visit, participants will have a brain magnetic resonance imaging (MRI) scan, electroencephalography (EEG), and electromyography (EMG). The MRI scan and EEG will be done during a movement task that involves the thumb, second finger, and fifth finger of one hand. EMG will be used to monitor movements and muscle activity.

- During the second testing visit, participants will receive a nerve block using anesthetic, followed by the MRI, EEG, EMG and movement task. The nerve block will temporarily numb and prevent the movement of parts of the hand and fingers.

- After the MRI scan and EEG recording, participants will be asked to rate how much control they felt they had over choosing whether to move, and how much control they felt they had in actually making the movements.


Description:

OBJECTIVE:

The primary objective of this study is to determine the brain regions responsible for the sense of volition and the associated sense of agency. Nerve blocks will be used to interfere with movement and/or sensory feedback from movement.

STUDY POPULATION:

Healthy subjects

DESIGN:

The initial studies will evaluate brain activity during the attempt to move different fingers after ulnar nerve block using functional magnetic resonance imaging (fMRI), electroencephalography (EEG) and surface electromyography (EMG). Subjects will attempt to move their fifth finger, their second finger and the thumb. These fingers will also be moved by the experimenter as a passive condition. The paradigm will be done once without anesthesia and once after ulnar nerve block. For both fMRI, EEG and EMG, analysis will be done with single event design. As our primary outcome, we hypothesize that subtracting the activation associated with attempting to move a paralyzed and anesthetized 5th finger, as well as the activation associated with the passive movement of the 5th finger without anesthesia, from that of normal movement of the same finger (without anesthesia), will show activation remaining in the inferior parietal lobule, which may be the area responsible for the feeling of agency. The activation associated with the attempt to move second finger, which will be paralyzed but only partially anesthetized, will be a secondary outcome of this study, as will other subtractions of activation associated with the three fingers.

OUTCOME MEASURES:

fMRI: Comparison of the BOLD signal in different brain regions with the different finger movements or attempted finger movements. The primary outcome measure is the difference in BOLD activation in the inferior parietal lobule between that associated with the attempt to move the 5th finger after anesthesia compared to the activation associated with moving the 5th finger actively minus the 5th finger being moved passively (with no anesthesia). Restated, from the trial with no anesthesia, the activation of active 5th finger movement (which reflects will (W), motor program (P), sensory feedback (S) and agency (A)) minus passive 5th finger movement (which reflects S only) will be compared to the activation from the attempt to move the 5th finger after ulnar block (which reflects W and P only). By comparing (W+P+S+A minus S) to (W+P) in the region of the inferior parietal lobule, we expect to see the activation associated with A, agency.

EEG/EMG: Movement-related cortical potentials will be compared with the different finger movements, using EMG to mark the onset of movement; these will be secondary outcomes.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 4, 2012
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility - INCLUSION CRITERIA:

Healthy right-handed subjects ranging from 18 to 55 will be included. All subjects should have a valid Clinical Center Medical Record Number.

EXCLUSION CRITERIA:

1. Healthy subjects younger than 18 years and older than 55 will be excluded.

2. Subjects with MRI findings consistent with organic brain lesions such as brain tumors, stroke, trauma or AVMs will be excluded.

3. Subjects with active significant medical or neurological disorders, or active Axis I psychiatric disorders, or requiring continuous treatment with drugs that affect the central nervous system will be excluded.

4. We will not include pregnant women because safety of high magnetic field to fetus is not established.

5. Subjects allergic to local anesthetics such as bupivacaine will be excluded.

6. Subjects unable to have an MRI due to claustrophobia or contraindications to MR scanning will be excluded.

7. Subjects who are left-handed will be excluded.

8. Subjects will be excluded who are taking anticoagulant or antiplatelet medications such as warfarin, heparin, clopidogrel, ticlopidine, or fondiparinux, or vitamin E in amounts greater than 1600 IU per day.

9. If subjects are taking daily aspirin therapy, this must be held for 7 days prior to the nerve block. If subjects are taking daily NSAIDs, these must be held for 12 hours prior to the nerve block. If these medications cannot be held for these periods, the subject will be excluded.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Blakemore SJ, Oakley DA, Frith CD. Delusions of alien control in the normal brain. Neuropsychologia. 2003;41(8):1058-67. — View Citation

Deecke L, Kornhuber HH. An electrical sign of participation of the mesial 'supplementary' motor cortex in human voluntary finger movement. Brain Res. 1978 Dec 29;159(2):473-6. — View Citation

Libet B, Gleason CA, Wright EW, Pearl DK. Time of conscious intention to act in relation to onset of cerebral activity (readiness-potential). The unconscious initiation of a freely voluntary act. Brain. 1983 Sep;106 (Pt 3):623-42. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1